Literature DB >> 9930702

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.

A Hutloff1, A M Dittrich, K C Beier, B Eljaschewitsch, R Kraft, I Anagnostopoulos, R A Kroczek.   

Abstract

The T-cell-specific cell-surface receptors CD28 and CTLA-4 are important regulators of the immune system. CD28 potently enhances those T-cell functions that are essential for an effective antigen-specific immune response, and the homologous CTLA-4 counterbalances the CD28-mediated signals and thus prevents an otherwise fatal overstimulation of the lymphoid system. Here we report the identification of a third member of this family of molecules, inducible co-stimulator (ICOS), which is a homodimeric protein of relative molecular mass 55,000-60,000 (M(r) 55K-60K). Matching CD28 in potency, ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, upregulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B cells. Unlike the constitutively expressed CD28, ICOS has to be de novo induced on the T-cell surface, does not upregulate the production of interleukin-2, but superinduces the synthesis of interleukin-10, a B-cell-differentiation factor. In vivo, ICOS is highly expressed on tonsillar T cells, which are closely associated with B cells in the apical light zone of germinal centres, the site of terminal B-cell maturation. Our results indicate that ICOS is another major regulator of the adaptive immune system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930702     DOI: 10.1038/16717

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  400 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.

Authors:  D A Mandelbrot; M A Oosterwegel; K Shimizu; A Yamada; G J Freeman; R N Mitchell; M H Sayegh; A H Sharpe
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 3.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 4.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

6.  EphB6 crosslinking results in costimulation of T cells.

Authors:  Hongyu Luo; Guang Yu; Yulian Wu; Jiangping Wu
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 7.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Adaptive resistance: a tumor strategy to evade immune attack.

Authors:  Sheng Yao; Lieping Chen
Journal:  Eur J Immunol       Date:  2013-02-04       Impact factor: 5.532

9.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

10.  Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Authors:  Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma
Journal:  Cancer Immunol Res       Date:  2013-07-31       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.